Guggenheim Initiates Coverage on Solid Biosciences (NASDAQ:SLDB)

Investment analysts at Guggenheim started coverage on shares of Solid Biosciences (NASDAQ:SLDB) in a research note issued on Friday, MarketBeat reports. The brokerage set a “buy” rating and a $26.00 price target on the stock. Guggenheim’s price objective would suggest a potential upside of 269.84% from the company’s current price.

SLDB has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Friday. Wedbush reiterated an “outperform” rating and issued a $14.00 target price on shares of Solid Biosciences in a research note on Wednesday, March 11th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of Solid Biosciences in a report on Friday. Finally, Citigroup reiterated a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.00.

Solid Biosciences Stock Down 1.3%

SLDB stock opened at $7.03 on Friday. The business has a 50 day moving average of $6.43 and a 200 day moving average of $5.80. The firm has a market cap of $547.71 million, a PE ratio of -3.48 and a beta of 2.65. Solid Biosciences has a twelve month low of $2.41 and a twelve month high of $8.72.

Solid Biosciences (NASDAQ:SLDB) last released its earnings results on Thursday, March 19th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.01. On average, research analysts expect that Solid Biosciences will post -2.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Solid Biosciences news, insider Jessie Hanrahan sold 26,535 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $6.44, for a total transaction of $170,885.40. Following the transaction, the insider owned 82,675 shares in the company, valued at approximately $532,427. This represents a 24.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin Tan sold 26,837 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $6.44, for a total transaction of $172,830.28. Following the sale, the chief financial officer directly owned 108,984 shares in the company, valued at approximately $701,856.96. The trade was a 19.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 597,672 shares of company stock worth $3,816,546 in the last quarter. Insiders own 1.90% of the company’s stock.

Hedge Funds Weigh In On Solid Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Legal & General Group Plc boosted its stake in shares of Solid Biosciences by 208.6% in the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after buying an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Solid Biosciences by 205.5% in the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after acquiring an additional 4,534 shares during the period. Creative Planning purchased a new position in Solid Biosciences in the second quarter worth about $57,000. Russell Investments Group Ltd. boosted its position in Solid Biosciences by 142.0% in the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after purchasing an additional 5,991 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in shares of Solid Biosciences by 233.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock valued at $74,000 after purchasing an additional 10,585 shares during the period. 81.46% of the stock is owned by institutional investors.

Key Headlines Impacting Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Guggenheim started coverage with a Buy and a $26 price target (implies ~272% upside from recent levels), giving formal street-level momentum and a large upside case for the stock. Guggenheim starts coverage (Benzinga)
• Positive Sentiment: Needham reaffirmed Buy with a $19 price target, signaling continued analyst conviction in the company’s clinical progress and longer-term value. Needham reaffirms buy (Benzinga)
• Positive Sentiment: Chardan reaffirmed its Buy rating and $15 target, adding to the cluster of upgrade/reaffirmation headlines that can attract investor attention and trading demand. Chardan reaffirms buy (TickerReport)
• Positive Sentiment: Solid reported positive interim Phase 1/2 INSPIRE data for SGT-003 at the 2026 MDA meeting; the readout highlights generally favorable tolerability in 41 dosed participants—this is the primary fundamental catalyst supporting higher valuations. SGT-003 interim data (GlobeNewswire)
• Neutral Sentiment: The company issued its Q4 and full-year 2025 results and broader business updates; the release contains operational context and program timelines that investors will parse for runway and development plans. Q4 & full-year 2025 results (FinanzNachrichten)
• Negative Sentiment: SLDB missed Q4 EPS expectations (reported -$0.53 vs. consensus -$0.48), underlining ongoing losses and near-term profitability risk that likely capped the stock’s upside today. Earnings press release (Quartr)

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.